Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction

... PETACH TIKVA Israel September 28 /- Healt...The Company will set a new record date for the future meeting expecte...(Due to the length of this URL it may be necessary to copy and paste...Closing of the transactions contemplated by the Agreement is subject t...

PETACH TIKVA, Israel, September 28 /PRNewswire-FirstCall/ -- Healthcare
Technologies Ltd. (NASDAQ: HCTL), announced today that it will reschedule
the extraordinary general meeting of its shareholders for the approval of
the Asset Purchase Agreement with NexGen Biofuels, Inc, Mac Bioventures
Inc. and Gamida for Life B.V., originally scheduled to be held on September
30, 2007, in order to allow shareholders additional time to fully consider
the proposed transaction. The Company noted that it is taking this step in
light of low shareholder participation, the considerable amount of
materials shareholders are to consider and reports of shareholders not
having received the proxy materials from brokers and banks.

The Company will set a new record date for the future meeting, expected
to be held in late November 2007 and will mail supplemental proxy materials
to its shareholders. Details regarding the rescheduled meeting will be
announced at a later date. The Proxy Statement previously circulated to the
Company's shareholders which details the transaction may be accessed online
on the website of the U.S. Securities and Exchange Commission at
http://www.sec.gov/Archives/edgar/data/835688/000117891307001798/exhibit_99
-1 .htm.

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

Closing of the transactions contemplated by the Agreement is subject to
the completion of due diligence by the parties, the receipt of the
necessary corporate, regulatory and third party approvals, including
Healthcare's shareholders and the approval of the Israeli District Court
and other closing conditions. No assurance can be given that the
transactions contemplated by the Agreement will close.

About Healthcare Technologies

Healthcare Technologies Ltd. through it subsidiaries and affiliates
Gamidor Diagnostics (1984) Ltd., Danyel Biotech Ltd. and Savyon Diagnostics
Ltd., specializes in the development, manufacturing and marketing of
clinical diagnostic test kits and provides services and tools to diagnostic
and biotech research professionals in laboratory and point of care sites
worldwide.

About NexGen Biofuels, Inc.

NexGen is operating in the business of alternative fuels. NexGen plans
to build and operate four ethanol and one biodiesel plant with production
primarily within the United States. NexGen is currently in the process of
acquiring and developing its proposed plants and has not conducted any
significant business operations or generated any operating revenues to
date. It is NexGen's intention to produce 100 million gallons of annual
ethanol production per ethanol site, and 100 million gallons of annual
biodiesel production.

SAFE HARBOR: This press release contains certain forward looking
statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. With the exception
of historical information contained herein, the matters discussed in this
press release involve risk and uncertainties. Actual results could differ
materially from those expressed in any forward looking statement made by or
on behalf of Healthcare Technologies Ltd. Many factors could cause the
actual results, performance or achievements of Healthcare or the above
described transaction to be materially different from any future results,
performance or achievements that may be expressed or implied by such
forward-looking statements, including, among others: satisfaction of the
closing conditions to the agreement; the agreement becoming subject to
termination if the Closing has not taken place on or before October 31,
2007; receipt of shareholder, regulatory and third party approvals,
including the approval of the District Court of Tel Aviv; the satisfaction
and completion of due diligence by the parties to the agreement; the
receipt by Healthcare of a satisfactory valuation of NexGen's assets; a
non-binding offer to purchase Healthcare's subsidiaries previously sent to
us by Inverness Medical Innovations, Inc., to which, as any negotiations
with Inverness would be a breach of the NexGen Agreement, Healthcare has
refrained from any discussions with Inverness. Readers are referred to the
documents filed by the company with the Securities and Exchange Commission,
specifically the Proxy Statement concerning the meeting and most recent
report on Form 20F that identifies important risks which could cause actual
results to differ from those contained in the forward looking statements.

(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...

(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...

(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...

(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...

(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...

(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...